Skin Neoplasms News - LARVOL Sigma

Skin Neoplasms

Welcome, Profile Billing Logout

62 Mechanisms of Action

|||||||||| Enrollment change: Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer (clinicaltrials.gov) - Feb 15, 2012
P0, N=18, Completed, Sponsor: The Cleveland Clinic
N=50 --> 18

|||||||||| Trial completion: Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer (clinicaltrials.gov) - Feb 15, 2012
P0, N=18, Completed, Sponsor: The Cleveland Clinic
N=50 --> 18 Not yet recruiting --> Completed

||||||||||  Erivedge (vismodegib) / Roche
New P2 trial, Surgery:  Vismodegib for Treatment of Basal Cell Carcinoma (clinicaltrials.gov) -  Feb 13, 2012
P2, N=81, Not yet recruiting,  Sponsor: Loma Linda University

||||||||||  Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases:  Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) -  Jan 31, 2012
P1, N=19, Active, not recruiting,  Sponsor: University of Southern California
Not yet recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Melanoma Detection by Oblique-Incidence Optical Spectroscopy (clinicaltrials.gov) - Jan 25, 2012
P=N/A, N=490, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=1000 --> 490

|||||||||| Trial completion: Melanoma Detection by Oblique-Incidence Optical Spectroscopy (clinicaltrials.gov) - Jan 25, 2012
P=N/A, N=490, Completed, Sponsor: M.D. Anderson Cancer Center
N=1000 --> 490 Active, not recruiting --> Completed

||||||||||  imatinib / Generic mfg.
Trial completion, Metastases:  S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov) -  Jan 11, 2012
P2, N=40, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  5-fluorouracil / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion:  S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer (clinicaltrials.gov) -  Jan 11, 2012
P2, N=80, Completed,  Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
New P2 trial, Tumor cell, Metastases:  Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells (clinicaltrials.gov) -  Dec 18, 2011
P2, N=5, Completed,  Sponsor: National Cancer Institute (NCI)

|||||||||| Enrollment open: Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers (clinicaltrials.gov) - Nov 30, 2011
P=N/A, N=55, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Recruiting

||||||||||  Tavo (tavokinogene telsaplasmid) / OncoSec
Enrollment open:  IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (clinicaltrials.gov) -  Nov 17, 2011
P2, N=15, Recruiting,  Sponsor: OncoSec Medical Incorporated
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting

|||||||||| Enrollment closed: PennSCAPE: Melanoma Risk Assessment & Tailored Intervention (clinicaltrials.gov) - Nov 15, 2011
P=N/A, N=300, Active, not recruiting, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting

||||||||||  Young TIL / National Cancer Institute
New P2 trial, Metastases:  Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) -  Nov 8, 2011
P2, N=35, Recruiting,  Sponsor: National Cancer Institute (NCI)

||||||||||  linsitinib (ASP7487) / Sling Therap
New P1/2 trial, Metastases:  Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) (clinicaltrials.gov) -  Nov 3, 2011
P1/2, N=67, Terminated,  Sponsor: OHSU Knight Cancer Institute

||||||||||  Genasense (oblimersen) / Genta
Trial completion, Metastases:  AGENDA: Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (clinicaltrials.gov) -  Nov 3, 2011
P3, N=300, Completed,  Sponsor: Genta Incorporated
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| New P2 trial: Skin Cancer Prevention in a Pediatric Population (clinicaltrials.gov) - Nov 2, 2011
P2, N=867, Completed, Sponsor: University of Colorado, Denver

|||||||||| Enrollment change: Natural History Study of Moles and Suspicious Melanoma (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=110 --> 20

|||||||||| Trial completion: Natural History Study of Moles and Suspicious Melanoma (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=20, Completed, Sponsor: National Cancer Institute (NCI)
N=110 --> 20 Recruiting --> Completed

|||||||||| New P1 trial: NPEF: Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer (clinicaltrials.gov) - Oct 31, 2011
P1, N=4, Completed, Sponsor: Children's Hospital & Research Center Oakland

|||||||||| Enrollment change: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
Recruiting --> Completed N=300 --> 99

|||||||||| Trial completion: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
N=300 --> 99 Recruiting --> Completed

|||||||||| Enrollment change: Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers (clinicaltrials.gov) - Oct 23, 2011
P=N/A, N=55, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed N=25 --> 55

|||||||||| Trial termination: ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients (clinicaltrials.gov) - Oct 19, 2011
P2, N=6, Terminated, Sponsor: DUSA Pharmaceuticals, Inc.
N=25 --> 55 Active, not recruiting --> Terminated; Orphan Drug Designation for this indication not granted

|||||||||| Enrollment change: ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients (clinicaltrials.gov) - Oct 19, 2011
P2, N=6, Terminated, Sponsor: DUSA Pharmaceuticals, Inc.
Active, not recruiting --> Terminated; Orphan Drug Designation for this indication not granted N=36 --> 6

|||||||||| New P3 trial: Melanoma Margins Excision Trial (clinicaltrials.gov) - Oct 18, 2011
P3, N=10500, Not yet recruiting, Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust

|||||||||| Surgery: Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project (clinicaltrials.gov) - Oct 13, 2011
P=N/A, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania

|||||||||| New P1 trial: Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation (clinicaltrials.gov) - Oct 4, 2011
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)

|||||||||| Trial withdrawal: Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy (clinicaltrials.gov) - Sep 25, 2011
P2, N=98, Withdrawn, Sponsor: Copenhagen University Hospital at Herlev
N=36 --> 6 Recruiting --> Withdrawn

||||||||||  Tavo (tavokinogene telsaplasmid) / OncoSec
New P2 trial:  IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (clinicaltrials.gov) -  Sep 25, 2011
P2, N=15, Recruiting,  Sponsor: OncoSec Medical Incorporated

|||||||||| Enrollment closed, Biopsy: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma (clinicaltrials.gov) - Sep 18, 2011
P1, N=100, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Withdrawn Recruiting --> Active, not recruiting

||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion, Surgery:  IMCX: Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery (clinicaltrials.gov) -  Aug 31, 2011
P3, N=70, Completed,  Sponsor: University of Ioannina
Recruiting --> Active, not recruiting Recruiting --> Completed

|||||||||| Enrollment change: Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients (clinicaltrials.gov) - Aug 17, 2011
P4, N=25, Completed, Sponsor: University of Zurich
Recruiting --> Completed N=2009 --> 25

|||||||||| Trial completion: Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients (clinicaltrials.gov) - Aug 17, 2011
P4, N=25, Completed, Sponsor: University of Zurich
N=2009 --> 25 Active, not recruiting --> Completed

|||||||||| Enrollment change, Metastases: Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=4, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=95 --> 4

|||||||||| Trial completion, Metastases: Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=4, Completed, Sponsor: National Cancer Institute (NCI)
N=95 --> 4 Recruiting --> Completed

|||||||||| Trial completion: T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant (clinicaltrials.gov) - Aug 10, 2011
P2b, N=100, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change: An Immunonutritional Approach to the Prevention of Skin Cancer (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=90, Completed, Sponsor: University of Manchester
Active, not recruiting --> Completed N=64 --> 90

|||||||||| Trial completion: An Immunonutritional Approach to the Prevention of Skin Cancer (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=90, Completed, Sponsor: University of Manchester
N=64 --> 90 Recruiting --> Completed